New ADHD Therapies Make Splash, Meet Payer Skepticism

Editor’s note: A previous version of this article incorrectly stated that Ehave, Inc. is the manufacturer of EndeavorRx. The digital therapeutic device is made by Akili Interactive. This version has been corrected.

In recent months, some innovative treatments have emerged for attention deficit hyperactivity disorder (ADHD), which affects millions of children and is one of the most common neurodevelopmental disorders in childhood. But because those therapies are so new — and in one case, very unconventional — payers appear reticent to change their coverage tactics to accommodate them.

© 2024 MMIT
Leslie Small

Leslie Small

Leslie has been working in journalism since 2009 and reporting on the health care industry since 2014. She has covered the many ups and downs of the Affordable Care Act exchanges, the failed health insurer mega-mergers, and hundreds of other storylines spanning subjects such as Medicaid managed care, Medicare Advantage, employer-sponsored insurance, and prescription drug coverage. As the managing editor of Health Plan Weekly and Radar on Drug Benefits, she writes and edits for both publications while overseeing a small team of reporters who also focus on the managed care sector. Before joining AIS Health, she was a senior editor for the e-newsletter Fierce Health Payer, and she started her career as a copy editor at multiple local newspapers. She graduated with a dual degree in journalism and political science from Penn State University.

Related Posts

iv-therapy
September 12

FDA’s Marks Issues ‘Provocative’ Call for Target Gene Therapy Profile That Includes Costs

READ MORE
September 12

News Briefs: CVS Challenges Lawmaker’s Claim of False Testimony

READ MORE
September 12

AMA Report Details PBM Market Concentration; PCMA Fires Back

READ MORE

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today